Hospitalised cancer patient

New NHS drug extends cancer patient’s life expectancy

Hundreds of cancer patients could survive twice as long, as the NHS launches new drug combatting lung cancer.

The drug, called durvalumab, keeps the cancer at bay for more than the two years – approximately four times longer than current combinations of chemotherapy and radiotherapy. The drug extends a patient’s life expectancy from around two-and-a-half years to five years, allowing them more precious time with their loved ones.

Now the drug has been approved by the National Institute for Health and Care Excellence the drug will be rolled out to more than 550 patients a year with non-small-cell lung cancer.

Dame Cally Palmer, National Cancer Director for NHS England said: “We are resolute in our ambition to fight the devastating effects of cancer and new pioneering treatments like durvalumab are a vital lifeline for people living with cancer – giving them more precious time with family and friends.

“Most of us know someone who has been diagnosed with cancer and it can affect people of all walks of life. The NHS has continued to prioritise cancer care throughout the pandemic and I urge anyone with concerns about symptoms they might be experiencing to come forward without delay and get checked, either at your GP or at one of our mobile lung cancer scanning units.”

The drug only takes one hour to administer and is given to patients every four weeks via an infusion into the vein. The drug then causes a protein called PD-L1 to attach to the cancer cells, making the body’s immune system attack and kill them.

Health and Social Care Secretary Sajid Javid said: “This is yet another example of how the NHS is pioneering innovative treatments to give cancer patients the best possible care and more time with their loved ones.

“We continue to improve outcomes for cancer patients across England and our upcoming 10-Year Cancer Plan will set out how we will lead Europe in cancer care.”

Durvalumab is the latest in an increasingly long line of treatments the NHS is making available to people with cancer, with sotorasib, mobocertinib and atezolizumab all having already been fast-tracked into production.

More information on the new drug is available here.

Jan/Feb

NHE January/February 2024

Boosting NHS productivity demands a healthy dose of realism

Dive into our latest edition for January/February!

Videos...

View all videos
Online Conference

Presenting

2024 Online Conferences

In partnership with our community of health sector leaders responsible for delivering the UK's health strategy across the NHS and the wider health sector, we’ve devised a collaborative calendar of conferences and events for industry leaders to listen, learn and collaborate through engaging and immersive conversation. 

All our conferences are CPD accredited, which means you can gain points to advance your career by attending our online conferences. Also, the contents are available on demand so you can re-watch at your convenience.

National Health Executive Podcast

Ep 41. The truth about drones in the NHS

In episode 41 of the National Health Executive podcast, we were joined by Dr Angela Smith, research fellow at Bournemouth University, and Andy Oakey, research fellow at the University of Southampton, to discuss the viability of drones within the NHS transport system.

More articles...

View all